Sargramostim for Active Crohn's Disease
Top Cited Papers
Open Access
- 26 May 2005
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (21) , 2193-2201
- https://doi.org/10.1056/nejmoa041109
Abstract
Sargramostim, granulocyte–macrophage colony-stimulating factor, a hematopoietic growth factor, stimulates cells of the intestinal innate immune system. Preliminary studies suggest sargramostim may have activity in Crohn's disease. To evaluate this novel therapeutic approach, we conducted a randomized, placebo-controlled trial.Keywords
This publication has 27 references indexed in Scilit:
- Colony-Stimulating Factor-1 Promotes Clonogenic Growth of Normal Murine Colonic Crypt Epithelial CellsIn VitroJournal of Interferon & Cytokine Research, 2004
- Granulocyte/macrophage colony-stimulating factor treatment improves alveolar epithelial barrier function in alcoholic rat lungAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2004
- Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitisGut, 2003
- Crohn’s disease and the NOD2 gene: a role for paneth cellsGastroenterology, 2003
- Nod2 Is a General Sensor of Peptidoglycan through Muramyl Dipeptide (MDP) DetectionJournal of Biological Chemistry, 2003
- Host Recognition of Bacterial Muramyl Dipeptide Mediated through NOD2Journal of Biological Chemistry, 2003
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2002
- Effect of Granulocyte-Macrophage Colony Stimulating Factor on Bacterial Translocation after Experimental Obstructive JaundiceThe European Journal of Surgery, 2001
- Concurrence of Inflammatory Bowel Disease and Multiple SclerosisMayo Clinic Proceedings, 2000
- Vascular Complications of Inflammatory Bowel DiseaseMayo Clinic Proceedings, 1986